Effects of ibandronate on pain,ALP,and Ca2+ levels in patients with bone metastasis of malignant tumors
Objective:To analyze the effects of ibandronate sodium on pain,Alkaline phosphatase(ALP),and Ca2+ levels in patients with bone metastasis of malignant tumors.Methods:The clinical data of 63 patients with bone metastasis of malignant tumors who were treated in our hospital from September 2021 to May 2023 were retrospectively analyzed.According to the different treatment methods,they were divided into the control group(treated with radiotherapy alone,30 cases)and the observation group(treated with ibandronate sodium based on the control group,33 cases).ALP and Ca2+ levels were detected by an automatic biochemical analyzer before and 6 weeks after treatment,and the pain degree of the two groups was evaluated by the numerical rating scale(NRS)after treatment.The quality of life was evaluated by the Generic Quality of Life Inventory(GQOLI-74),and adverse reactions were recorded.Results:After treatment,the NRS scores were decreased in the two groups,and the NRS score in the observation group was lower than the control group after 6 weeks of treatment(P<0.05).After treatment,the levels of ALP and Ca2+ in the two groups decreased,and the levels of ALP and Ca2+ in the observation group were lower than those in the control group after 6 weeks of treatment(P<0.05).After treatment,the GQOLI-74 scores of the two groups increased,and the GQOLI-74 score of the observation group was higher than that of the control group after 6 weeks of treatment(P<0.05).The incidence of adverse reactions in the control group(0.00%)was lower than that in the observation group(9.09%)(P>0.05).Conclusion:Ibandronate sodium can effectively relieve the pain of patients with malignant tumors and bone metastasis,reduce the levels of ALP and Ca2+,and improve their quality of life,with a certain safety.
NETL
NSTL
万方数据
